Q-omics provides the consensus-scored FAM210B profile across patient tissues and cancer cell-line models. FAM210B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FAM210B is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, FAM210B RNA expression shows 18,724 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, COAD, and KIRP as cancer lineages where FAM210B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM210B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM210B survival associations across molecular data types. FAM210B RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM210B RNA expression–survival associations across cancer types. High FAM210B expression shows unfavorable associations in UCS and LGG, but favorable associations in KIRC, MESO, LUAD and UCEC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for FAM210B RNA expression.
This table summarizes FAM210B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 7. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM210B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM210B shows lower tumor expression in BRCA and UCEC and higher tumor expression in COAD, LUSC, CHOL and STAD. The COAD box plot shows higher FAM210B RNA expression in tumor versus normal tissue (log2 FC = +0.641, t-test p = .003).
This table shows molecular features associated with FAM210B in patient tissues and cancer cell lines. In patient samples, FAM210B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM210B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
